KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Inventory (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Inventory for 14 consecutive years, with $79.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Inventory changed N/A to $79.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $79.4 million, a N/A change, with the full-year FY2024 number at $54.3 million, down 29.86% from a year prior.
  • Inventory was $79.4 million for Q3 2025 at Supernus Pharmaceuticals, up from $54.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $91.5 million in Q4 2022 to a low of $50.2 million in Q1 2021.
  • A 5-year average of $76.7 million and a median of $83.2 million in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: surged 105.69% in 2021, then fell 29.86% in 2024.
  • Supernus Pharmaceuticals' Inventory stood at $86.0 million in 2021, then rose by 6.49% to $91.5 million in 2022, then fell by 15.44% to $77.4 million in 2023, then dropped by 29.86% to $54.3 million in 2024, then soared by 46.24% to $79.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Inventory are $79.4 million (Q3 2025), $54.3 million (Q4 2024), and $77.4 million (Q4 2023).